全文获取类型
收费全文 | 3331篇 |
免费 | 219篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 85篇 |
儿科学 | 105篇 |
妇产科学 | 60篇 |
基础医学 | 362篇 |
口腔科学 | 189篇 |
临床医学 | 483篇 |
内科学 | 703篇 |
皮肤病学 | 45篇 |
神经病学 | 354篇 |
特种医学 | 120篇 |
外国民族医学 | 1篇 |
外科学 | 325篇 |
综合类 | 93篇 |
预防医学 | 260篇 |
眼科学 | 15篇 |
药学 | 214篇 |
中国医学 | 1篇 |
肿瘤学 | 138篇 |
出版年
2022年 | 25篇 |
2021年 | 41篇 |
2020年 | 30篇 |
2019年 | 59篇 |
2018年 | 58篇 |
2017年 | 32篇 |
2016年 | 49篇 |
2015年 | 46篇 |
2014年 | 69篇 |
2013年 | 139篇 |
2012年 | 142篇 |
2011年 | 168篇 |
2010年 | 104篇 |
2009年 | 80篇 |
2008年 | 136篇 |
2007年 | 148篇 |
2006年 | 152篇 |
2005年 | 166篇 |
2004年 | 116篇 |
2003年 | 100篇 |
2002年 | 100篇 |
2001年 | 89篇 |
2000年 | 107篇 |
1999年 | 69篇 |
1998年 | 46篇 |
1997年 | 28篇 |
1996年 | 51篇 |
1995年 | 36篇 |
1994年 | 43篇 |
1993年 | 48篇 |
1992年 | 73篇 |
1991年 | 68篇 |
1990年 | 66篇 |
1989年 | 75篇 |
1988年 | 83篇 |
1987年 | 75篇 |
1986年 | 64篇 |
1985年 | 58篇 |
1984年 | 51篇 |
1983年 | 41篇 |
1982年 | 30篇 |
1981年 | 19篇 |
1980年 | 29篇 |
1979年 | 30篇 |
1978年 | 25篇 |
1977年 | 21篇 |
1976年 | 21篇 |
1975年 | 20篇 |
1974年 | 25篇 |
1973年 | 23篇 |
排序方式: 共有3553条查询结果,搜索用时 15 毫秒
51.
52.
Khadija EL. Mouaden D.S. Chauhan M.A. Quraishi Lahcen Bazzi 《Sustainable Chemistry and Pharmacy》2020
A facile single-step synthesis was performed to cross-link chitosan with thiocarbohydrazide to yield thiocarbohydrazide-chitosan (TC-Cht) which was for the first time evaluated as an inhibitor for corrosion of stainless steel in 3.5% NaCl solution. A comprehensive electrochemical analysis employing electrochemical impedance spectroscopy (EIS), potentiodynamic polarization (PDP), and cyclic voltammetry (CV) was undertaken and showed that the TC-Cht acts by adsorption on the steel surface and exhibits mixed type behavior with predominantly cathodic nature. The adsorption of TC-Cht molecules on the surface of stainless steel followed the Langmuir isotherm. The TC-Cht showed a high inhibition efficiency of >94% at 500 mg L?1 concentration. Surface investigation using SEM and EDX supported the inhibitor adsorption on the steel surface. 相似文献
53.
Objective
Research on patient involvement in decision-making in psychiatry has focused on first encounters. This study investigated what decisions are made, level of patient involvement and factors influencing patient involvement in ongoing outpatient visits.Methods
72 visits conducted by 20 psychiatrists were video recorded. Patients had a diagnosis of depression or schizophrenia.Results
On average, there was one medication related and one other decision per visit. Some psychiatrists involved patients more in decisions, as did female psychiatrists. Involvement was lower when patients had more negative symptoms.Conclusion
Involvement in decision-making appears to be influenced by the individual psychiatrist and specific symptoms but not visit length.Practice implications
It is noteworthy that patient involvement is not influenced by length of the visit given that this would be a barrier in busy clinical practice. The next step would be to identify the communication patterns of psychiatrists who involve patients more in decision-making. 相似文献54.
55.
56.
D A Morrow E M Antman S M Snapinn C H McCabe P Theroux E Braunwald 《European heart journal》2002,23(3):223-229
AIMS: We evaluated the TIMI Risk Score for Unstable Angina and Non-ST Elevation Myocardial Infarction for predicting clinical outcomes and the efficacy of tirofiban in non-ST elevation acute coronary syndromes. METHODS AND RESULTS: Developed in TIMI 11B, the risk score is calculated as the sum of seven presenting characteristics (age > or =65 years, > or =3 cardiac risk factors, documented coronary disease, recent severe angina, ST deviation > or =0.5 mm, elevated cardiac markers, prior aspirin use). The risk score was validated in the PRISM-PLUS database (n=1915) and tested for interaction with the efficacy of tirofiban+heparin vs heparin alone. The risk score revealed an increasing gradient of risk for death, myocardial infarction or recurrent ischaemia at 14 days ranging from 7.7-30.5% (P<0.001). Dichotomized at the median, patients with a score > or =4 derived a greater relative risk reduction with tirofiban (P((Interaction))=0.025). Among patients with normal creatine kinase myocardial bands, the risk score showed a 3.5-fold gradient of risk (P<0.001) and identified a population that derived significant benefit from tirofiban (RR 0.73, P=0.027). CONCLUSION: The TIMI Risk Score is a simple clinical tool for risk assessment that may aid in the early identification of patients who should be considered for treatment with potent antiplatelet therapy. 相似文献
57.
Donald A. Weiner Carolyn McCabe David C. Hueter Thomas J. Ryan William B. Hood 《American heart journal》1978,96(4):458-462
To determine the significance of anginal chest pain during exercise testing, a series of 302 patients undergoing coronary arteriography with exercise testing was reviewed. Of the 302 patients, 85 had ischemic ECG changes and chest pain (Group I); 87 patients had ischemic ECG changes but no chest pain (Group II); 25 patients had chest pain but no ischemic ECG changes (Group III); 105 patients had neither chest pain nor ischemic ECG changes (Group IV). Coronary artery disease was present in 95 per cent of Group I, 75 per cent of Group II, 72 per cent of Group III, and 28 per cent of Group IV. Of those patients with coronary disease, multiple vessels were involved in 94 per cent of Group I, 51 per cent of Group II, 67 per cent of Group III, and 21 per cent of Group IV. The predictive value for presence and extent of coronary disease showed Group I > Groups II and III > Group IV (p < 0.025). We conclude that (1) anginal chest pain during exercise testing predicts the presence and extent of coronary disease more accurately than its absence; (2) the presence of chest pain even without an ischemic ECG response during exercise testing appears to be as predictive of coronary disease as an ischemic ECG response alone; and (3) the combination of anginal chest pain during exercise testing and an ischemic ECG response is highly predictive of multivessel coronary artery disease. 相似文献
58.
59.
60.
Stuart A. Morgan Emma L. McCabe Laura L. Gathercole Zaki K. Hassan-Smith Dean P. Larner Iwona J. Bujalska Paul M. Stewart Jeremy W. Tomlinson Gareth G. Lavery 《Proceedings of the National Academy of Sciences of the United States of America》2014,111(24):E2482-E2491
The adverse metabolic effects of prescribed and endogenous glucocorticoid (GC) excess, Cushing syndrome, create a significant health burden. We found that tissue regeneration of GCs by 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), rather than circulating delivery, is critical to developing the phenotype of GC excess; 11β-HSD1 KO mice with circulating GC excess are protected from the glucose intolerance, hyperinsulinemia, hepatic steatosis, adiposity, hypertension, myopathy, and dermal atrophy of Cushing syndrome. Whereas liver-specific 11β-HSD1 KO mice developed a full Cushingoid phenotype, adipose-specific 11β-HSD1 KO mice were protected from hepatic steatosis and circulating fatty acid excess. These data challenge our current view of GC action, demonstrating 11β-HSD1, particularly in adipose tissue, is key to the development of the adverse metabolic profile associated with circulating GC excess, offering 11β-HSD1 inhibition as a previously unidentified approach to treat Cushing syndrome.Estimates suggest that 1–2% of the population of the United States and United Kingdom take prescribed glucocorticoids (GCs) for the treatment of a broad spectrum of inflammatory and autoimmune diseases (1, 2). Despite the efficacy of GCs, 70% of patients experience an adverse systemic side-effect profile. The resultant Cushingoid features include central obesity, proximal myoatrophy, hypertension, skin thinning, osteoporosis, hepatic steatosis, insulin resistance, and type 2 diabetes (3, 4). Collectively, this contributes to increased risk of cardiovascular morbidity and mortality (5, 6). These features are replicated in patients with much rarer endogenous GC excess (Cushing syndrome), as first described by Harvey Cushing in 1932 (7). Current medical therapeutic options that reverse the tissue-specific consequences of hypercortisolism are limited.GC availability and action depend not only upon circulating levels but also on tissue-specific intracellular metabolism by 11β-hydroxysteroid dehydrogenases (11β-HSDs). Key metabolic tissues including liver, adipose tissue, and skeletal muscle express 11β-HSD type 1 (11β-HSD1), which coverts inactive cortisone to active cortisol [11-dehydrocorticosterone (11DHC) and corticosterone (CORT) in rodents, respectively] (8). In the setting of GC excess, the relative contribution to the metabolic effects induced by GCs of simple delivery of active GCs (cortisol or CORT) to a target tissue, compared with the regeneration of active GCs by 11β-HSD1 within the tissue, has not been determined.Type 2 11β-HSD (11β-HSD2) is predominately expressed in the kidney, colon, and salivary gland and catalyzes the inactivation of cortisol to cortisone (CORT to 11DHC in rodents). This not only protects the mineralocorticoid receptor from occupancy by cortisol but also crucially provides substrate for 11β-HSD1 in peripheral tissues.Transgenic animal models have highlighted the critical role of 11β-HSD1 in the regulation of metabolic phenotype in individual tissues. Mice overexpressing 11β-HSD1, specifically in adipose tissue, develop visceral obesity, insulin resistance, dyslipidemia, and hypertension (9, 10). Similarly, liver-specific 11β-HSD1 overexpression results in insulin resistance and hypertension, but not obesity (11). Importantly, circulating CORT levels were not elevated in either model, suggesting increased intracellular GC availability underpins the observed phenotypes. Indeed, this was confirmed in the adipose-specific 11β-HSD1–overexpressing mice, where twofold higher intraadipose CORT levels were recorded in comparison with WT controls (9). Ultimately, this has led to the development of selective 11β-HSD1 inhibitors as a potential treatment for patients with diabetes, obesity, and hypertension (12, 13).Although it is clear that 11β-HSD1 has a critical role to play in governing GC availability, its potential dynamic role in the setting of GC excess has not been fully explored (14–16). We have previously reported a patient with Cushing disease who was protected from the classic Cushing phenotype, owing to a functional defect in 11β-HSD1 activity, as evidenced by serum and urinary biomarkers (17). Based on this observation, we have hypothesized that tissue intrinsic 11β-HSD1 activity is the major determinant of the manifestations of GC excess and that 11β-HSD1 deletion will ameliorate the associated metabolic abnormalities. To determine the relative tissue-specific contribution to this effect, we have generated tissue-specific 11β-HSD1 deletions in liver and adipose tissue. 相似文献